2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-171099
    SC-919 2245949-62-4 98%
    SC-919 (LI-2124) is an orally active and selective inhibitor targeting inositol hexakisphosphate kinases (IP6K, including IP6K1, IP6K2, and IP6K3 subtypes) with an IC50 value of 0.65 nM for IP6K3. SC-919 reduces the production of inositol pyrophosphates (e.g., InsP₇) by inhibiting IP6K, thereby suppressing XPR1-mediated cellular phosphate export and increasing intracellular ATP levels. SC-919 is promising for research of chronic kidney disease (CKD)-related hyperphosphataemia.
    SC-919
  • HY-171241
    Imolamine 318-23-0 98%
    Imolamine is a potent antiplatelet aggregation agent, is a phenyl aminoxidiazole derivative. Imolamine has the potential for the research of coronary heart disease.
    Imolamine
  • HY-171249
    CDD-1431 3034216-31-1 98%
    CDD-1431 is a low-nanomolar selective kinase inhibitors of BMPR2, with Kiapp value of 20.6 nM. CDD-1431 suppresses BRE-reporter activity, with an IC50 of 4.87 μM. BMP controls cellular processes across many tissue types, including the kidney, skeletal muscle, heart, and reproductive organs. BMP induces ectopic bone formation.
    CDD-1431
  • HY-171335
    ST-115 1840873-90-6
    ST-115 is a highly potent and very specific aminopeptidase P2 inhibitor. ST-115 can be used in the research of ischemic stroke.
    ST-115
  • HY-171461
    CGS 24592 147923-04-4 98%
    CGS 24592 is an orally active, selective and potent neutral endopeptidase 24.11 (NEP) inhibitor with an IC50 value of 1.6 nmol/L. CGS 24592 reduces the degradation of atrial natriuretic peptide (ANP), increases the concentration of ANP in the plasma, and reduces blood pressure. CGS 24592 is promising for research of cardiovascular disease, such as hypertension and congestive heart failure.
    CGS 24592
  • HY-171464
    Lp(a)-IN-5 2924841-79-0 98%
    Lp(a)-IN-5 (Compound A) is an orally active lipoprotein (a) (Lp(a)) inhibitor. Lp(a)-IN-5 inhibits the assembly of Apo(a) and ApoB proteins with an IC50 value of 0.41 nM. Lp(a)-IN-5 is promising for research of diseases related to elevated plasma Lp(a) levels, such as cardiovascular diseases.
    Lp(a)-IN-5
  • HY-171782
    Amidepin 90405-00-8
    Amidepin is a new type of antiarrhythmic compound. Amidepin has the activity of regulating cardiac electrical activity. The main regulatory mechanism of amidepin involves ion channel or receptor interaction. Amidepin can be used for the study of arrhythmias.
    Amidepin
  • HY-171798
    BAM-2101 115178-28-4
    BAM-2101 is an ergoline derivative with antihypertensive activity. BAM-2101 is orally active and lowers blood pressure in spontaneously hypertensive rats.
    BAM-2101
  • HY-172094
    AMPK-IN-6 98%
    AMPK-IN-6 (compound 13a) is potent AMPK inhibitor with an IC50 value of 0.093 µM. AMPK-IN-6 induces apoptosis and inhibits autophagy. AMPK-IN-6 shows antiproliferative activity. AMPK-IN-6 has the potential for the research of pulmonary arterial hypertension.
    AMPK-IN-6
  • HY-172141
    Ebio2 98%
    Ebio2 is a potent KCNQ2 activator.
    Ebio2
  • HY-172181
    NSC380324 98%
    NSC380324 is a P2Y12 receptor antagonist, possessing antiplatelet activity, and can be utilized in research on atherosclerotic cardiovascular diseases.
    NSC380324
  • HY-172227
    S-15176 148089-70-7 98%
    S-15176 is an inhibitor of the mitochondrial permeability transition pore (PTP). S-15176 inhibits mitochondrial swelling induced by tert-butylhydroperoxide with an IC50 value of 45.7 μM. S-15176 inhibits PTP opening, prevents mitochondrial membrane potential dissipation and NAD(P)H oxidation, and increases mitochondrial calcium loading capacity. S-15176 is promising for research of ischemia-reperfusion injury.
    S-15176
  • HY-172231
    Hexolame 110346-23-1 98%
    Hexolame is an estrogen receptors agonist with dual anticoagulant and estrogenic properties. Hexolame binds to estrogen receptors to induce anticoagulant effects by modulating clotting factors or platelet activity. Hexolame is promising for research of prostatic cancer and prevention of thrombosis.
    Hexolame
  • HY-172234
    PF-06842874 2516247-98-4 98%
    PF-06842874 is a CDK4/Cyclin D1 and CDK6/Cyclin D3 inhibitor (Ki values are 62 and 130 nM, respectively). PF-06842874 can be used in the research of pulmonary arterial hypertension and cancer.
    PF-06842874
  • HY-172281
    DSPE-PEG1000-CCK8 98%
    DSPE-PEG1000-CCK8 is a PEG compound which composed of DSPE and a Cholecystokinin-8 (CCK8). Cholecystokinin-8 has the activity of peptide regulating gallbladder contraction and digestive system function. DSPE-PEG1000-CCK8 can be used for drug delivery.
    DSPE-PEG1000-CCK8
  • HY-172342
    MitoA bromide
    MitoA (bromide) is a mitochondria-targeted H2S probe, which can be used to assess relative changes in mitochondrial levels of H2S in vivo. MitoA (bromide) can accumulate inside mitochondria within tissues in vivo due to tryphenylphosphonium (TPP) cation. MitoA (bromide) can be studied in research on myocardial ischemia.
    MitoA bromide
  • HY-172400
    FXIa-IN-16 3046390-69-3 98%
    FXIa-IN-16 (Compound 43) is an orally active and selective Factor XIa (FXIa) inhibitor with an IC50 of 0.19 nM. FXIa-IN-16 exhibits strong anticoagulant and antithrombotic activities and shows good safety in mice. FXIa-IN-16 can be used in the research related to the treatment of thrombosis.
    FXIa-IN-16
  • HY-172417
    Becondogrel 1416696-44-0 98%
    Becondogrel (2-Oxoclopidogrel) is the metabolite of Clopidogrel (HY-15283). Becondogrel irreversibly inhibits P2Y12 receptor, thereby inhibiting platelet aggregation and thrombosis.
    Becondogrel
  • HY-172522
    (±)11(12)-DiHET
    (±)11(12)-DiHET can be converted to a metabolite – 7,8-dihydroxy-hexadecadienoic acid (DHHD). (±)11(12)-DiHET is able to produce relaxation in porcine coronary artery rings. (±)11(12)-DiHET can be studied in research about arterial smooth muscle metabolism.
    (±)11(12)-DiHET
  • HY-172541
    LN6023 hydrochloride 98%
    LN6023 (hydrochloride) (Compound 27) is a CXCR7 agonist. LN6023 (hydrochloride) induces the recruitment of β-arrestin in HEK293T cells expressing human CXCR7 (EC50 = 3.5 µM). LN6023 (hydrochloride) reduces the surface level of P-selectin in isolated and washed human platelets. LN6023 (hydrochloride) can be used to study platelet-mediated thrombosis.
    LN6023 hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity